Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma.

ABSTRACT:

Importance

Acute adverse events (AEs) after chimeric antigen receptor (CAR) T-cell infusion are well documented, but less information is available regarding the long-term toxic effects.

Objective

To assess the occurrence of late AEs for adult patients with large B-cell lymphoma (LBCL) treated with commercially available CD19-targeted CAR T cells.

Design, setting, and participants

A prospective, observational, clinical practice cohort study was conducted from September 1, 2018, to December 31, 2022, among 172 adult patients in 6 Spanish hospitals who received CD19-targeted CAR T-cell therapy for relapsed or refractory LBCL and survived at least 3 months after infusion, without subsequent antilymphoma therapy.

Exposure

Treatment with tisagenlecleucel or axicabtag

SUBMITTER: Camacho-Arteaga L 

PROVIDER: S-EPMC11862965 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature